Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.00 USD
Change Today -0.31 / -2.74%
Volume 1.1M
NKTR On Other Exchanges
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Howard W. Robin

Chief Executive Officer, President and Director, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 75 board members in 3 different organizations across 3 different industries.

See Board Relationships
As of Fiscal Year 2013


Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Therapeutics since January 15, 2007. From January 2001 to June 2001, he served as Chief Operating Officer and President of Prime Holdings & Investments Inc. He served as President and Chief Executive Officer of Sirna Therapeutics, Inc. since July 2001. Prior to Sirna Therapeutics, ...

Read Full Background

Corporate Headquarters*

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships*

Director, Member of Compensation Committee, Member of Corporate Governance and Nominating Committee and Member of Research and Development Committee
Chief Executive Officer, President and Director
Chief Executive Officer, President and Director


BS 1974
Fairleigh Dickinson University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$831,247

Stock Options*

All Other Compensation$15,039
Exercisable Options3,193,748
Exercisable Options Value$9,675,599
Unexercisable Options681,252
Unexercisable Options Value$1,863,401
Total Value of Options$11,539,000
Total Number of Options3,875,000

Total Compensation*

Total Annual Cash Compensation$1,502,486
Total Short Term Compensation$831,247
Other Long Term Compensation$15,039
Total Calculated Compensation$3,569,651
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.00 USD -0.31


Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director and Member of Strategic Operations Committee
Emergent BioSolutions, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at